ZeClinics and the University of California join forces against epilepsy

by Gemma Escarré,

ZeClinics, a zebrafish preclinical Contract Research Organisation (CRO) and member of CataloniaBio & HealthTech, has signed a licensing agreement with the Office of Technology Management of the University of California in San Francisco. 

With this, the company located at the Barcelona Biomedical Research Park (PRBB) leads licensing and business development efforts on behalf of the university for the commercialization of drug discovery assays in childhood epilepsy by using scn1Lab mutant zebrafish.

More information

We recomend the videointerview to Dr Davide d'Amico, co-founder and CEO of ZeClinics, to learn more about this animal model for preclinical research.


To comment, please login or create an account